|
1) Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003; 101: 4660-6
|
|
|
|
2) Raman SV, Mehta R, Walker J, et al. Cardiovascular magnetic resonance in endocardial fibroelastosis. J Cardiovasc Magn Reson. 2005; 7: 391-3
|
|
|
|
|
|
3) Florian S, Esterbauer H, Binder T, et al. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFR alpha, classification by WHO criteria, and response to therapy with imatinib. Leuk Res. 2006; 30: 1201-5
|
|
|
|
|
|
4) Atallah E, Durand JB, Kantarjian HM, et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood. 2007; Apr 20 [Epub ahead of print]
|
|
|
|
|
|
5) Verweij J, Casali PG, Kotasek D, et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer. 2007; 43: 974-8
|
|
|
|
|
|
6) Kil KE, Ding YS, Lin KS, et al. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol. 2007; 34: 153-63
|
|
|
|
|
|
7) Batzios S, Michalopoulos A, Kaklamanis L, et al. Angiosarcoma of the heart: case report and review of the literature. Anticancer Res. 2006; 26(6C): 4837-42
|
|
|
|
|
|
8) Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med. 2006; 12: 908-16
|
|
|
|
|
|
9) Saad SY, Alkharfy KM, Arafah MM. Cardiotoxic effects of arsenic trioxide/imatinib mesilate combination in rats. J Pharm Pharmacol. 2006; 58: 567-73
|
|
|
|
|
|
10) Schellings MW, Baumann M, van Leeuwen RE, et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension. 2006; 47: 467-74
|
|
|
|
|
|
11) Park YH, Park HJ, Kim BS, et al. BNP as a marker of the heart failure in the treatment of imatinib mesylate. Cancer Lett. 2006; 243: 16-22
|
|
|
|
|
|
12) Onitilo AA, Kio EA, Singh AK, et al. Cytogenetic remission with imatinib therapy in hypereosinophilic syndrome with trisomy 8 and resolution of severe cardiac dysfunction. Leuk Lymphoma. 2005; 46: 1667-70
|
|
|
|
|
|
13) Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest. 2005; 115: 2811-21
|
|
|
|
|
|
14) Anghel G, De Rosa L, Ruscio C, et al. Efficacy of imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome and severe heart involvement. Tumori. 2005; 91: 67-70. Review
|
|
|
|
|
|
15) Nykanen AI, Krebs R, Tikkanen JM, et al. Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. Transplantation. 2005; 79: 182-9
|
|
|
|
|
|
16) Leiferman KM, Gleich GJ. Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol. 2004; 113: 50-8
|
|
|
|
|
|
17) Gotlib V, Darji J, Bloomfield K, et al. Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leuk Lymphoma. 2003; 44: 1609-13
|
|
|
|
|
|
18) Sohn SK, Kim JG, Kim DH, et al. Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration. Br J Haematol. 2003; 121: 469-72
|
|
|
|
|